口腔抗敏大健康

Search documents
登康口腔(001328):关注Q3新品推广节奏 看好口腔抗敏龙头成长
Xin Lang Cai Jing· 2025-08-26 00:37
Core Viewpoint - The company reported a strong performance in 1H25, with revenue of 840 million and a year-on-year growth of 19.7%, while net profit attributable to shareholders reached 90 million, up 17.6%, aligning with expectations [1] Revenue Breakdown - E-commerce channels led revenue growth, with online sales increasing by 86.6% to 300 million, accounting for 35.7% of total revenue, a rise of 12.8 percentage points year-on-year [2] - Adult oral care revenue grew by 20.6% to 760 million, driven by adult toothpaste and toothbrush sales, which increased by 23% and 4.2% to 680 million and 80 million, respectively [2] - Children's oral care revenue slightly declined by 0.5% to 53 million, with toothpaste sales up 1.2% to 38 million, while toothbrush sales fell by 4.6% to 15 million [2] Profitability Analysis - The gross margin for Q2 was 49.6%, showing a year-on-year increase of 4.2 percentage points but a decrease of 5.9 percentage points quarter-on-quarter, influenced by channel shipment rhythms [3] - The gross margin for adult toothpaste and toothbrushes increased by 5.5 and 8 percentage points to 53.6% and 40.9%, respectively [3] - E-commerce channel gross margin rose by 11.9 percentage points to 62.5% [3] Future Outlook - The company recently launched a new bioactive toothpaste, which is expected to accelerate e-commerce growth in Q3, with a focus on high-end products [4] - The company is well-positioned in the oral health sector, with a solid offline distribution base and a strong brand image, which supports continued online growth [4] - The company aims to enhance its product portfolio in oral beauty care, creating long-term growth opportunities [4] Earnings Forecast and Valuation - The earnings forecast remains unchanged, with the current stock price corresponding to P/E ratios of 39 and 34 for 2025 and 2026, respectively [5] - The company maintains an outperform rating and target price, reflecting an 8% upside potential based on P/E ratios of 42 and 36 for 2025 and 2026 [5]